OutcomeImprovementEffect · pTreatmentControl
risk of death
150.8% higher · RR 2.51 · p = 1.00
150.8% higherRR 2.51p = 1.00
1 of 252 (0.4%)
0 of 128 (0.0%)
treatment 1 of 252 (0.4%), control 0 of 128 (0.0%)combined bebtelovimab armscontinuity correction due to zero events
risk of death
200.8% higher · RR 3.01 · p = 0.50
200.8% higherRR 3.01p = 0.50
1 of 127 (0.8%)
0 of 128 (0.0%)
treatment 1 of 127 (0.8%), control 0 of 128 (0.0%)bamlanivimab, etesevimab, and bebtelovimabcontinuity correction due to zero events
risk of hospitalization
27.0% higher · RR 1.27 · p = 1.00
27.0% higherRR 1.27p = 1.00
5 of 252 (2.0%)
2 of 128 (1.6%)
treatment 5 of 252 (2.0%), control 2 of 128 (1.6%)combined bebtelovimab arms
risk of hospitalization
51.2% higher · RR 1.51 · p = 0.68
51.2% higherRR 1.51p = 0.68
3 of 127 (2.4%)
2 of 128 (1.6%)
treatment 3 of 127 (2.4%), control 2 of 128 (1.6%)bamlanivimab, etesevimab, and bebtelovimab
risk of hospitalization
2.4% higher · RR 1.02 · p = 1.00
2.4% higherRR 1.02p = 1.00
2 of 125 (1.6%)
2 of 128 (1.6%)
treatment 2 of 125 (1.6%), control 2 of 128 (1.6%)bebtelovimab
risk of no viral clearance
35.5% lower · RR 0.64 · p = 0.07
35.5% lowerRR 0.64p = 0.07
33 of 252 (13.1%)
26 of 128 (20.3%)
treatment 33 of 252 (13.1%), control 26 of 128 (20.3%)day 7 persistently high viral load, combined bebtelovimab armsNNT 14primary outcome
risk of no viral clearance
38.0% lower · RR 0.62 · p = 0.13
38.0% lowerRR 0.62p = 0.13
16 of 127 (12.6%)
26 of 128 (20.3%)
treatment 16 of 127 (12.6%), control 26 of 128 (20.3%)day 7 persistently high viral load, bamlanivimab, etesevimab, and bebtelovimabNNT 13primary outcome
risk of no viral clearance
33.0% lower · RR 0.67 · p = 0.18
33.0% lowerRR 0.67p = 0.18
17 of 125 (13.6%)
26 of 128 (20.3%)
treatment 17 of 125 (13.6%), control 26 of 128 (20.3%)day 7 persistently high viral load, bebtelovimabNNT 15primary outcome